@article{Nieto_Gruschkus_Valdez_Jones_Anderlini_Hosing_Popat_Qazilbash_Kebriaei_Alousi_Saini_Srour_Rezvani_Ramdial_Barnett_Gulbis_Shigle_Ahmed_Iyer_Lee_Nair_Parmar_Steiner_Dabaja_Pinnix_Gunther_Cuglievan_Mahadeo_Khazal_Chuang_Champlin_Shpall_Andersson_2022, place={Pavia, Italy}, title={Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis}, volume={107}, url={https://haematologica.org/article/view/haematol.2021.278311}, DOI={10.3324/haematol.2021.278311}, abstractNote={<p>High-dose chemotherapy and autologous stem-cell transplant (HDC/ASCT) is standard treatment for chemosensitive relapsed classical Hodgkin lymphoma, although outcomes of high-risk relapse (HRR) patients remain suboptimal. We retrospectively analyzed all HRR classical Hodgkin lymphoma patients treated with HDC/ASCT at our institution between 01/01/2005 and 12/31/2019. HRR criteria included primary refractory disease/relapse within 1 year, extranodal extension, B symptoms, requiring more than one salvage line, or positron emission tomography (PET)-positive disease at ASCT. All patients met the same ASCT eligibility criteria. We treated 501 patients with BEAM (n=146), busulphan/melphalan (BuMel) (n=38), gemcitabine( Gem)/BuMel (n=189) and vorinostat/Gem/BuMel (n=128). The Gem/BuMel and vorinostat/Gem/BuMel cohorts had more HRR criteria and more patients with PET-positive disease at ASCT. Treatment with brentuximab vedotin (BV) or anti-PD1 prior to ASCT, PET-negative disease at ASCT, and maintenance BV increased over time. BEAM and BuMel predominated in earlier years (2005-2007), GemBuMel and BEAM in middle years (2008-2015), and vorinostat/GemBuMel and BEAM in later years (2016-2019). The median follow-up is 50 months (range, 6-186). Outcomes improved over time, with 2-year progressionfree survival (PFS)/overall survival (OS) rates of 58%/82% (2005-2007), 59%/83% (2008-2011), 71%/94% (2012-2015) and 86%/99% (2016- 2019) (P&lt;0.0001). Five-year PFS/OS rates were 72%/87% after vorinostat/ GemBuMel, 55%/75% after GemBuMel, 45%/61% after BEAM, and 39%/57% after BuMel (PFS: P=0.0003; OS: P&lt;0.0001). These differences persisted within the PET-negative and PET-positive subgroups. Prior BV and vorinostat/GemBuMel were independent predictors of more favorable outcome, whereas primary refractory disease, ≥2 salvage lines, bulky relapse, B symptoms and PET-positivity at ASCT correlated independently with unfavorable outcomes. In conclusion, post-HDC/ASCT outcomes of patients with HRR classic Hodgkin lymphoma have improved over the last 15 years. Pre-ASCT BV treatment and optimized synergistic HDC (vorinostat/GemBuMel) were associated with this improvement.</p&gt;}, number={4}, journal={Haematologica}, author={Nieto, Yago and Gruschkus, Stephen and Valdez, Benigno C. and Jones, Roy B. and Anderlini, Paolo and Hosing, Chitra and Popat, Uday and Qazilbash, Muzaffar and Kebriaei, Partow and Alousi, Amin and Saini, Neeraj and Srour, Samer and Rezvani, Katayoun and Ramdial, Jeremy and Barnett, Melissa and Gulbis, Alison and Shigle, Terri Lynn and Ahmed, Sairah and Iyer, Swaminathan and Lee, Hun and Nair, Ranjit and Parmar, Simrit and Steiner, Raphael and Dabaja, Bouthaina and Pinnix, Chelsea and Gunther, Jillian and Cuglievan, Branko and Mahadeo, Kris and Khazal, Sajad and Chuang, Hubert and Champlin, Richard and Shpall, Elizabeth J. and Andersson, Borje S.}, year={2022}, month={Apr.}, pages={899-908} }